COVID-19 Update: See the latest on our visitor policy here. Learn More
An investigator-initiated Phase I study of SELINEXOR in combination with Bevacizumab and Atezolizumab in newly diagnosed advanced Hepatocellular Carcinoma
The goal of this clinical research study is to find out if the oral drug Selinexor taken along with bevacizumab and atezolizumab is effective in treating advanced Hepatocellular Carcinoma.
Primary Objective: To determine the safety and tolerability of SELINEXOR with bevacizumab and atezolizumab as first-line treatment of advanced HCC Secondary Objectives: To evaluate the efficacy of the combination of SELINEXOR with bevacizumab and atezolizumab as first-line treatment of HCC.
Immunotherapy; Therapy (NOS)
Atezolizumab (Tecentriq); Avastin (Bevacizumab); Bevacizumab (); KPT-330 (Selinexor); Selinexor ()
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.